All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On Saturday 1st December 2018, an oral abstract session took place at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. During Session 627 (Aggressive lymphoma - results from retrospective/observational studies: outcomes with CD-19 CAR‑T therapy and checkpoint blockade in the real world setting) Abstract 96 was presented by Dahlia Sano M.D., MD Anderson Cancer Center (MDACC), Houston, TX.
The objective of the study was to compare the safety and efficacy outcomes of patients aged < 65 years versus patients aged ≥ 65 years with relapsed/refractory large B-cell lymphoma and who had been treated with axicabtagene ciloleucel (axi-cel). Data from patients treated with axi-cel between 6/18/2015 and 09/17/2018 at MDACC were retrospectively analyzed and reviewed.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox